Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression profiling of endothelial-mesenchymal transition in cerebral arteriovenous malformation

ABSTRACT: Gene expression profiling of endothelial-mesenchymal transition in cerebral arteriovenous malformation

PROVIDER: PRJNA1091184 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Gene expression profiling of endothelial-mesenchymal transition in cerebral arteriovenous malformation

Project description:To investigate the endothelial-mesenchymal transition in cerebral arteriovenous malformation. We performed gene expression profiling analysis using the data obtained from RNA-seq of CD31+CD45- brain cells in Cdh5cre;Mgpflox/flox mice with or without tamoxifen induction.

2024-05-30 | GSE262300 | GEO

Histone Modification in Cerebral Arteriovenous Malformation

Project description:Histone Modification in Cerebral Arteriovenous Malformation

| PRJNA1027297 | ENA

Histone Modification in Cerebral Arteriovenous Malformation

2024-05-30 | GSE245171 | GEO

Brain Arteriovenous Malformation Genetics Study

Project description:Brain Arteriovenous Malformation Genetics Study

| PRJNA648440 | ENA

Brain Arteriovenous Malformation Genetics Study

Project description:Brain Arteriovenous Malformation Genetics Study

| PRJNA648439 | ENA

Elevated Endothelial Sox2 Causes Lumen Disruption and Cerebral AVMs

Project description:Lumen integrity in vascularization requires fully differentiated endothelial cells (ECs). Here, we report that endothelial-mesenchymal transitions (EndMTs) emerged in ECs of cerebral arteriovenous malformation (AVMs) and caused disruption of the lumen or lumen disorder. We show that excessive Sry-box 2 (Sox2) signaling was responsible for the EndMTs in cerebral AVMs. EC-specific suppression of Sox2 normalized endothelial differentiation and lumen formation, and improved the cerebral AVMs. Epigenetic studies showed that induction of Sox2 altered the cerebral-endothelial transcriptional landscape, and identified jumonji domain-containing protein 5 (JMJD5) as a direct target of Sox2. Sox2 interacted with JMJD5 to induce EndMTs in cerebral ECs. Furthermore, we utilized a high throughput system to identify the beta-adrenergic antagonist pronethalol as an inhibitor of Sox2 expression. Treatment with pronethalol stabilized endothelial differentiation and lumen formation, which limited the cerebral AVMs.

2019-04-12 | GSE129644 | GEO

Inhibition of endothelial histone deacetylase 2 shifts endothelial-mesenchymal transitions in cerebral arteriovenous malformation models.

Project description:Cerebral arteriovenous malformations (AVMs) are the most common vascular malformations worldwide and the leading cause of hemorrhagic strokes that may result in crippling neurological deficits. Here, using newly generated mouse models, we uncovered that cerebral endothelial cells (ECs) acquired mesenchymal markers and caused vascular malformations. Interestingly, we found that limiting endothelial histone deacetylase 2 (HDAC2) prevented cerebral ECs from undergoing mesenchymal differentiation and reduced cerebral AVMs. We found that endothelial expression of HDAC2 and enhancer of zeste homolog 1 (EZH1) was altered in cerebral AVMs. These alterations changed the abundance of H4K8ac and H3K27me in the genes regulating endothelial and mesenchymal differentiation, which caused the ECs to acquire mesenchymal characteristics and form AVMs. Together, this investigation demonstrated that the induction of HDAC2 altered specific histone modifications, which resulted in mesenchymal characteristics in the ECs and cerebral AVMs. The results provided insight into the epigenetic impact on AVMs.

| S-EPMC11290970 | biostudies-literature

Characterization of Endothelial Cells Associated with Cerebral Arteriovenous Malformation.

Project description:Introduction:Cerebral arteriovenous malformation (cAVM) is a disease characterized by the angiogenesis and remodeling of veins. However, whether vascular endothelial cells (ECs) exhibit morphological and functional changes during cAVM remains unclear. This study aimed to investigate the role of ECs in the pathogenesis of cAVM. Methods:Rat model of cAVM was established by anastomosing the common carotid artery with the external jugular vein. The digital subtraction angiography (DSA), HE, Masson and immunohistochemical staining were performed to evaluate the model. ECs were isolated from AVM rat model or control rats, and characterized by MTT, cell scratch, and tube formation assays. The secretion of vascular endothelial growth factor (VEGF) was detected by ELISA. Results:AVM rat model showed typical pathological characteristics of cAVM. In addition, the proliferation, migration and tube formation abilities of ECs of arterialized vein (AV-ECs) were significantly better than those of ECs of normal vein (NV-ECs). Moreover, the levels of secreted VEGF were significantly higher in AV-ECs than in NV-ECs. Conclusion:AV-ECs isolated from AVM rat model showed increased proliferation, migration and angiogenesis and may be potential target for the treatment of cAVM.

| S-EPMC7182449 | biostudies-literature

Inflammation and neutrophil extracellular traps in cerebral cavernous malformation

Project description:Cerebral Cavernous Malformation (CCM) is a brain vascular disease with various neurological symptoms. In this study, we describe the inflammatory profile in CCM and show for the first time the formation of neutrophil extracellular traps (NETs) in rodents and humans with CCM. Through RNA-seq analysis of cerebellum endothelial cells from wild-type mice and mice with anendothelial cell-specific ablation of the Ccm3 gene (Ccm3iECKO), we show that endothelial cells from Ccm3iECKO mice have anincreased expression of inflammation-related genes.

2023-10-31 | GSE246373 | GEO

Inflammation and neutrophil extracellular traps in cerebral cavernous malformation

Project description:Inflammation and neutrophil extracellular traps in cerebral cavernous malformation

| PRJNA1032618 | ENA